ClinicalTrials.gg

Program

delgocitinib

Also written as “Delgocitinib cream”, “Delgocitinib” and “LEO 124249”.

Its studies are mostly in Eczema · Psoriasis · Dermatitis, Atopic · Alopecia Areata · Lichen Sclerosus et Atrophicus, led by LEO Pharma.

Furthest: phase 3, since Apr 29, 202121 company-led studies, 2 open or runningNext primary completion: Jun 4, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LEO Pharma212 open or runningphase 3since Apr 29, 2021Sep 25, 2015Jun 4, 2027phase 2 · NCT07013201

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Sep 25, 2015.

  1. May 20, 2019Phase 2 study in Lupus Erythematosus, DiscoidNCT03958955 · 27 enrolled · United States, Denmark, France and more
  2. Apr 22, 2020Phase 1 study in HealthyNCT04361136 · 35 enrolled · Germany
  3. Mar 18, 2021Phase 1 study in HealthyNCT04807751 · 60 enrolled · Germany
  4. Apr 29, 20212 phase 3 studies in Chronic Hand EczemaNCT04872101, NCT04871711
  5. Jun 29, 2021Phase 3 study in Chronic Hand EczemaNCT04949841 · 801 enrolled · Belgium, Canada, Denmark and more
  6. Jul 5, 2021Early phase 1 study in HealthyNCT05050279 · 40 enrolled · United Kingdom
  7. Feb 18, 2022Phase 3 study in Chronic Hand EczemaNCT05259722 · 513 enrolled · Austria, Canada, France and more
  8. Apr 11, 2022Phase 2 study in Frontal Fibrosing AlopeciaNCT05332366 · 35 enrolled · United States
  9. Apr 27, 2022Phase 3 study in Chronic Hand EczemaNCT05355818 · 98 enrolled · Australia, Belgium, Canada and more
  10. Jul 18, 2022Phase 1 study in Chronic Hand EczemaNCT05486117 · 15 enrolled · Germany
  11. Aug 16, 2023Phase 3 study in Skin DiseasesNCT06004050 · 362 enrolled · China
  12. Jun 2, 2025Phase 2 study in PsoriasisNCT07013201 · 135 planned · United States, Canada, Germany and more
  13. Jan 9, 2026Phase 3 study in Lichen Sclerosus et AtrophicusNCT07335588 · 652 planned · United States, Canada, United Kingdom
  14. Nov 9, 2026Primary completion moved from 2026-12-14 to 2027-06-04Date moved laterphase 2 · +6 months · NCT07013201

Ahead

  1. Jun 4, 2027Primary completion: phase 2 study in PsoriasisNCT07013201
  2. Mar 10, 2028Primary completion: phase 3 study in Lichen Sclerosus et AtrophicusNCT07335588

TargetBeta

“Janus Kinase (JAK) inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07335588Lichen Sclerosus et Atrophicus · United States, Canada, United Kingdom3RecruitingMar 10, 2028652
NCT07013201Psoriasis · United States, Canada, Germany and more2RecruitingJun 4, 2027135
NCT06004050Skin Diseases · China3CompletedDec 16, 2024362
NCT05486117Chronic Hand Eczema · Germany1CompletedNov 22, 202215
NCT05355818Chronic Hand Eczema · Australia, Belgium, Canada and more3CompletedDec 5, 202498
NCT05332366Frontal Fibrosing Alopecia · United States2CompletedFeb 13, 202335
NCT05259722Chronic Hand Eczema · Austria, Canada, France and more3CompletedNov 8, 2023513
NCT05050279Healthy · United KingdomEarly 1CompletedJan 4, 202240
NCT04949841Chronic Hand Eczema · Belgium, Canada, Denmark and more3CompletedSep 18, 2023801
NCT04872101Chronic Hand Eczema · Belgium, Canada, Denmark and more3CompletedDec 27, 2022473
NCT04871711Chronic Hand Eczema · Canada, France, Germany and more3CompletedOct 31, 2022487
NCT04807751Healthy · Germany1CompletedJul 30, 202160
NCT04361136Healthy · Germany1CompletedMay 30, 202035
NCT03958955Lupus Erythematosus, Discoid · United States, Denmark, France and more2TerminatedApr 15, 202027
NCT03826901Dermatitis, Atopic · United States, Canada1CompletedOct 29, 202146
NCT03725722Dermatitis, Atopic · United States, Australia, Canada2CompletedMay 19, 2020251
NCT03683719Chronic Hand Eczema · United States, Denmark, Germany2CompletedMar 6, 2020258
NCT03325296Alopecia Areata · Denmark2TerminatedMay 16, 201813
NCT02695940Inverse Psoriasis · Germany2CompletedSep 201669
NCT02664805Chronic Hand Eczema · Germany2CompletedJul 201691
NCT02561585Alopecia Areata · United States2CompletedDec 201640

How it is read

Names in the registry

  • “Delgocitinib cream”, 9 entries
  • “Delgocitinib”, 6 entries
  • “LEO 124249”, 2 entries
  • “LEO 124249 ointment”, 1 entry
  • “Delgocitinib capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.